PURPOSE OF REVIEW: IDH1/2 mutations occur in up to 70% of low-grade gliomas and secondary glioblastomas. Mutation of these enzymes reduces the wildtype function of the enzyme (conversion of isocitrate to α-ketoglutarate) while conferring a new enzymatic function, the production of D-2-hydroxyglutarate (D-2-HG) from α-ketoglutarate (α-KG). However, it is unclear how these enzymatic changes contribute to tumorigenesis. Here, we discuss the recent studies that demonstrate how IDH1/2 mutation may alter the metabolism and epigenome of gliomas, how these changes may contribute to tumor formation, and opportunities they might provide for molecular targeting. RECENT FINDINGS: Metabolomic studies of IDH1/2 mutant cells have revealed alterations in glutamine, fatty acid, and citrate synthesis pathways. Additionally, D-2-HG produced by IDH1/2 mutant cells can competitively inhibit α-KG-dependent enzymes, including histone demethylases and DNA hydroxylases, potentially leading to a distinct epigenetic phenotype. Alterations in metabolism and DNA methylation present possible mechanisms of tumorigenesis. SUMMARY: Recent attempts to improve outcomes for glioma patients have resulted in incremental gains. Studies of IDH1/2 mutations have provided mechanistic insights into tumorigenesis and potential avenues for therapeutic intervention. Further study of IDH1/2 mutations might allow for improved therapeutic strategies.
PURPOSE OF REVIEW: IDH1/2 mutations occur in up to 70% of low-grade gliomas and secondary glioblastomas. Mutation of these enzymes reduces the wildtype function of the enzyme (conversion of isocitrate to α-ketoglutarate) while conferring a new enzymatic function, the production of D-2-hydroxyglutarate (D-2-HG) from α-ketoglutarate (α-KG). However, it is unclear how these enzymatic changes contribute to tumorigenesis. Here, we discuss the recent studies that demonstrate how IDH1/2 mutation may alter the metabolism and epigenome of gliomas, how these changes may contribute to tumor formation, and opportunities they might provide for molecular targeting. RECENT FINDINGS: Metabolomic studies of IDH1/2 mutant cells have revealed alterations in glutamine, fatty acid, and citrate synthesis pathways. Additionally, D-2-HG produced by IDH1/2 mutant cells can competitively inhibit α-KG-dependent enzymes, including histone demethylases and DNA hydroxylases, potentially leading to a distinct epigenetic phenotype. Alterations in metabolism and DNA methylation present possible mechanisms of tumorigenesis. SUMMARY: Recent attempts to improve outcomes for glioma patients have resulted in incremental gains. Studies of IDH1/2 mutations have provided mechanistic insights into tumorigenesis and potential avenues for therapeutic intervention. Further study of IDH1/2 mutations might allow for improved therapeutic strategies.
Authors: Mary A Selak; Sean M Armour; Elaine D MacKenzie; Houda Boulahbel; David G Watson; Kyle D Mansfield; Yi Pan; M Celeste Simon; Craig B Thompson; Eyal Gottlieb Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: Elaine R Mardis; Li Ding; David J Dooling; David E Larson; Michael D McLellan; Ken Chen; Daniel C Koboldt; Robert S Fulton; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Devin P Locke; Vincent J Magrini; Rachel M Abbott; Tammi L Vickery; Jerry S Reed; Jody S Robinson; Todd Wylie; Scott M Smith; Lynn Carmichael; James M Eldred; Christopher C Harris; Jason Walker; Joshua B Peck; Feiyu Du; Adam F Dukes; Gabriel E Sanderson; Anthony M Brummett; Eric Clark; Joshua F McMichael; Rick J Meyer; Jonathan K Schindler; Craig S Pohl; John W Wallis; Xiaoqi Shi; Ling Lin; Heather Schmidt; Yuzhu Tang; Carrie Haipek; Madeline E Wiechert; Jolynda V Ivy; Joelle Kalicki; Glendoria Elliott; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark A Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Daniel C Link; Matthew J Walter; Timothy A Graubert; John F DiPersio; Richard K Wilson; Timothy J Ley Journal: N Engl J Med Date: 2009-08-05 Impact factor: 91.245
Authors: Martijn Kranendijk; Eduard A Struys; Emile van Schaftingen; K Michael Gibson; Warsha A Kanhai; Marjo S van der Knaap; Jeanne Amiel; Neil R Buist; Anibh M Das; Johannis B de Klerk; Annette S Feigenbaum; Dorothy K Grange; Floris C Hofstede; Elisabeth Holme; Edwin P Kirk; Stanley H Korman; Eva Morava; Andrew Morris; Jan Smeitink; Rám N Sukhai; Hilary Vallance; Cornelis Jakobs; Gajja S Salomons Journal: Science Date: 2010-09-16 Impact factor: 63.714
Authors: Robert J Harris; Jingwen Yao; Ararat Chakhoyan; Catalina Raymond; Kevin Leu; Linda M Liau; Phioanh L Nghiemphu; Albert Lai; Noriko Salamon; Whitney B Pope; Timothy F Cloughesy; Benjamin M Ellingson Journal: Magn Reson Med Date: 2018-04-06 Impact factor: 4.668
Authors: Jasmina S Redzic; Leonora Balaj; Kristan E van der Vos; Xandra O Breakefield Journal: Semin Cancer Biol Date: 2014-04-28 Impact factor: 15.707
Authors: Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash Journal: Cancer Rep (Hoboken) Date: 2018-09-23
Authors: Y-L Wang; J Yao; A Chakhoyan; C Raymond; N Salamon; L M Liau; P L Nghiemphu; A Lai; W B Pope; N Nguyen; M Ji; T F Cloughesy; B M Ellingson Journal: AJNR Am J Neuroradiol Date: 2019-05-16 Impact factor: 3.825
Authors: Yanxin Lu; Jakub Kwintkiewicz; Yang Liu; Katherine Tech; Lauren N Frady; Yu-Ting Su; Wendy Bautista; Seog In Moon; Jeffrey MacDonald; Matthew G Ewend; Mark R Gilbert; Chunzhang Yang; Jing Wu Journal: Cancer Res Date: 2017-02-15 Impact factor: 12.701